**CENTRAL PHARMACEUTICALS LIMITED**
**STATEMENT OF FINANCIAL POSITION**
**AS AT 30 JUNE 2026**

| Particulars | Note | Amount in Taka 30 June 2026 | Amount in Taka 30 June 2025 |
|---|---|---|---|
| **ASSETS** | | | |
| **Non-Current Assets** | | | |
| Property, Plant & Equipment | **3.00** | 1,030,238,238 | 1,049,669,062 |
| Intangible Assets | **4.00** | 74,920 | 83,244 |
| | | **1,030,313,158** | **1,049,752,306** |
| **Current Assets** | | | |
| Inventories | **5.00** | 18,467,498 | 10,327,489 |
| Spare Parts & Supplies | **6.00** | 10,632,740 | 11,675,560 |
| Advances, Deposits & Pre-payments | **7.00** | 287,062,356 | 287,060,405 |
| Accounts Receivable | **8.00** | 67,947,491 | 68,904,410 |
| Cash & Cash Equivalents | **9.00** | 1,246,364 | 1,234,285 |
| | | **385,356,449** | **379,202,149** |
| **TOTAL ASSETS** | | **1,415,669,607** | **1,428,954,455** |
| **SHAREHOLDERS' EQUITY & LIABILITY** | | | |
| **Shareholders' Equity** | | | |
| Share Capital | **10.00** | 1,198,008,440 | 1,198,008,440 |
| Revaluation Reserve | **11.00** | 732,690,537 | 732,690,537 |
| Retained Earnings | **12.00** | (1,127,957,025) | (1,107,382,834) |
| | | **802,741,952** | **823,316,144** |
| **Non-Current Liabilities** | | | |
| Long Term Loan | **13.00** | 231,989,485 | 231,977,819 |
| Deferred Tax Liabilities | **14.00** | 26,428,137 | 29,390,908 |
| | | **258,417,622** | **261,368,727** |
| **Current Liabilities** | | | |
| Current Portion of Long Term Loan | **15.00** | 36,496,932 | 36,496,932 |
| Sundry Creditors | **16.00** | 29,053,146 | 19,249,508 |
| Liabilities for Expenses | **17.00** | 1,379,473 | 1,125,764 |
| Cash Dividend payables | **17.01** | 859,383 | 859,383 |
| Others Payable | **18.00** | 5,962,694 | 5,962,694 |
| Provision for Tax Liabilities | **19.00** | 280,758,405 | 280,575,304 |
| | | **354,510,033** | **344,269,585** |
| **Total Liabilities** | | **612,927,655** | **605,638,312** |
| **TOTAL SHAREHOLDERS' EQUITY & LIABILITY** | | **1,415,669,607** | **1,428,954,455** |
| **Net Asset Value per Share** | **29.00** | **6.70** | **6.87** |

The accompanying notes 1 to 48 form an integral part of these financial Statements
Signed as per our separate report of the same date

**Company Secretary** **Managing Director** **Chairman**

**Mohammad Shibbir Hossain FCA**
Partner
Ashraf Uddin & Co.
Chartered Accountants
DVC:

Date:
Place: Dhaka

# CENTRAL PHARMACEUTICALS LIMITED

## STATEMENT OF PROFIT OR LOSS & OTHER COMPREHENSIVE INCOME

## FOR THE YEAR ENDED 30 JUNE 2026

| Particulars | Note | Amount in Taka 2025-2026 | Amount in Taka 2024-2025 |
|---|---|---|---|
| Turnover | **20.00** | 36,620,272 | 33,058,631 |
| Cost of Goods Sold | **21.00** | (48,226,208) | (44,059,175) |
| **Gross Profit/(Loss)** | | **(11,605,936)** | **(11,000,544)** |
| **Less: Operating Expenses** | | | |
| Administrative Expenses | **22.00** | (11,325,622) | (11,336,781) |
| Selling & Distribution Expenses | **23.00** | (411,840) | (360,580) |
| Financial Expenses | **24.00** | (16,968) | (6,459) |
| | | **(11,754,430)** | **(11,703,820)** |
| **Net Operating Income** | | **(23,360,366)** | **(22,704,364)** |
| **Add: Non-Operating Income** | | | |
| Other Income | **25.00** | 6,505 | 6,486 |
| **Profit before contribution to WPPF** | | **(23,353,861)** | **(22,697,878)** |
| Less: Contribution to WPPF | **26.00** | - | - |
| **Net Profit/(Loss) before Tax** | | **(23,353,861)** | **(22,697,878)** |
| **Less: Provision for Current Tax** | | | |
| Current Tax | **27.00** | (183,101) | (198,352) |
| Deferred Tax | **27.01** | 2,962,771 | 914,511 |
| | | **2,779,670** | **716,159** |
| **Net Profit/(Loss) after Tax** | | **(20,574,191)** | **(21,981,719)** |
| **Earnings per Share** | **28.00** | **(0.17)** | **(0.18)** |

The accompanying notes 1 to 48 form an integral part of these financial Statements
Signed as per our separate report of the same date

**Company Secretary** **Managing Director** **Chairman**

**Mohammad Shibbir Hossain FCA**
Partner
Ashraf Uddin & Co.
Chartered Accountants
DVC:

Date:
Place: Dhaka

# CENTRAL PHARMACEUTICALS LIMITED

## STATEMENT OF CHANGES IN EQUITY

### FOR THE YEAR ENDED 30 JUNE 2026

Amount in Taka

| Particulars | Share Capital | Revaluation Reserve | Retained Earnings | Total |
|---|---|---|---|---|
| Balance as on 01-July-2025 | 1,198,008,440 | 732,690,538 | (1,107,382,834) | 823,316,144 |
| Addition During the year | - | - | - | - |
| Net profit (after tax) transferred from statement of Profit or (Loss) & Other Comprehensive Income | - | - | (20,574,191) | (20,574,191) |
| **Balance as on 30-06-2026** | **1,198,008,440** | **732,690,538** | **(1,127,957,025)** | **802,741,953** |

**For the year ended 30 June, 2025**

Amount in Taka

| Particulars | Share Capital | Revaluation Reserve | Retained Earnings | Total |
|---|---|---|---|---|
| Balance as on 01-July-2024 | 1,198,008,440 | 732,690,538 | (1,085,401,115) | 845,297,863 |
| Net profit (after tax) transferred from statement of Profit or (Loss) & Other Comprehensive Income | - | - | (21,981,719) | (21,981,719) |
| **Balance as on 30-06-2025** | **1,198,008,440** | **732,690,538** | **(1,107,382,833)** | **823,316,145** |

**Company Secretary** | **Managing Director** | **Chairman**

# CENTRAL PHARMACEUTICALS LIMITED

## STATEMENT OF CASH FLOWS

### FOR THE YEAR ENDED 30 JUNE 2026

| Particulars | Note | Amount in Taka 2025-2026 | Amount in Taka 2024-2025 |
|---|---|---|---|
| **A. Cash Flows from Operating Activities** | | | |
| Collection from Customers & Others | 31.01 | 33,829,016 | 32,762,528 |
| Payment to Supplier & Others | | (33,798,018) | (33,282,939) |
| Income Tax Paid | 31.02 | (1,951) | (1,946) |
| **Net Cash Generated from Operating Activities** | | **29,047** | **(522,357)** |
| **B. Cash Flows from Investing Activities** | | | |
| Acquisition of Property Plant & Equipment | | - | - |
| **Net Cash used in Investing Activities** | | **-** | **-** |
| **C. Cash Flows from Financing Activities** | | | |
| Long Term Loan Receipt/(Repayment) | | - | - |
| Short Term Loan Receipt/(Repayment) | | - | - |
| Financial Expenses | | (16,968) | (6,459) |
| **Net Cash Generated from Financing Activities** | | **(16,968)** | **(6,459)** |
| **E. Net Cash Increase in Cash & Cash Equivalents (A+B+C)** | | **12,079** | **(528,816)** |
| **F.** Cash & Cash Equivalents at the Beginning of the year | | 1,234,285 | 1,763,101 |
| **G. Cash & Cash Equivalents at the End of the year (E-F)** | | **1,246,364** | **1,234,285** |
| **Net Operating Cash Flows per Share** | 30.00 | **0.00** | **(0.00)** |

**Company Secretary** **Managing Director** **Chairman**

# Central Pharmaceuticals Limited

**Notes, Comprising a Summary of Significant Accounting Policies and Other Explanatory Information**
**For the period ended 30 June 2026**

## 1.00 The Company & It's Operations:

### 1.01 Legal form of the Company:

The Company was incorporated in 13 November, 1980 as a 'Private' Company limited by shares and registered with the Registrar of Joint Stock Companies & Firms of Bangladesh under the Companies Act, 1913 vide Registration No. C-8514(353). On 20 December 2010, the Company registered itself as a Public Limited Company under the Companies Act, 1994.

The Company is listed with both Dhaka Stock Exchange Limited (DSE) and Chittagong Stock Exchange Limited (CSE) at 22 July 2013 and 15 July 2013 respectively and trading of the share of the Company has been started from 14 August 2013.

### 1.02 Address of the Registered & Corporate Office:

The registered, corporate office and its factory is situated in its own premises at 2-A/1, South-West Darus Salam Road, Mirpur-01, Dhaka-1216.

### 1.03 Nature of Business Activities:

The principal activities of the Company throughout the period continued to be manufacturing and marketing of quality medicine.

## 2.00 Summary of Significant Accounting & Valuation Principles:

### 2.01 Basis of Preparation & Presentation of the Financial Statements:

The financial statements have been prepared and the disclosures of information were made in accordance with the requirements of the Companies Act, 1994, IAS and IFRS. The Statement of Financial Position and Statement of Comprehensive Income have been prepared according to IAS-1 "Presentation of Financial Statements" based on accrual basis of accounting following going concern assumption under generally accepted accounting principles and practices in Bangladesh and Statement of Cash Flows according to IAS-7 "Statement Cash Flows".

### 2.02 Accounting Convention & Assumption:

The financial statements are prepared under the historical cost convention.

### 2.03 Principal Accounting Policies:

The specific accounting policies have been selected and applied by the Company's management for significant transactions and events that have a material effect within the Framework for preparation and presentation of the financial statements. Financial statements have been prepared and presented in compliance with IAS-1 "Presentation of Financial Statements". The previous year's figures were formulated according to the same accounting principles. Compared to the previous year, there were no significant changes in the accounting and valuation policies affecting the financial position and performance of the Company. However, changes made to the presentation are explained in the note for each respective item. Accounting and valuation methods are disclosed for reasons of clarity. The Company classified the expenses using the function of expenses method as per IAS-1.

**2.03.1 Legal Compliance:**

The financial statements have been prepared and the disclosures of information were made in accordance with the requirements of the Companies Act, 1994, Securities and Exchange Rules 1987, Listing Regulations of Dhaka Stock Exchange Limited (DSE) and Chittagong Stock Exchange Limited (CSE) and IASs. On the basis of these regulations, International Accounting Standards (IAS) & International Financial Reporting Standards (IFRS) were applied with the applicable standards at the Statement of Financial Position date.

**2.03.2 Critical Accounting Estimates, Assumptions & Judgments:**

The preparation of the financial statements are in conformity with IFRS requires the use of certain critical accounting estimates. It also requires management to exercise its judgment in the process of applying the Company's accounting policies.

**2.04 Going Concern:**

The Company has adequate resources to continue in operation for the foreseeable future. For this reasons the directors continue to adopt going concern basis in preparing the financial statements. The current credit facilities and resources of the Company provides sufficient fund to meet the present requirements of existing business.

**2.05 Off Setting:**

"In compliance to IAS-1 and IAS-32, offsetting is done for a particular vendor or customer when the following conditions are met:

- Each of the two parties owes the other determinable amounts;
- The entity has the right to set off against the amount owed by other party;
- The entity intends to offset;
- The right of setoff is legally enforceable."

**2.06 Components of the Financial Statements:**

According to the International Accounting Standards (IAS)-1 "Presentation of Financial Statements" the complete set of Financial Statements includes the following components":

- Statement of Financial Position as at 30 June 2026;
- Statement of Profit or Loss and Other Comprehensive Income for the period ended 30 June 2026;
- Statement of Changes in Equity for the period ended 30 June 2026;
- Statement of Cash Flows for the period ended 30 June 2026;

&

- Accounting Policies and Explanatory Notes.

**2.07 Application of Standards:**

The following IASs are applicable for the financial statements for the year under review:

IAS-1 Presentation of Financial Statements;
IAS-2 Inventories;
IAS-7 Cash Flow Statements;
IAS-8 Accounting Policies, Changes in Accounting Estimates and Errors;
IAS-10 Events after the Balance Sheet Date;
IAS-12 Income Taxes;
IAS-16 Property, Plant & Equipment;
IAS-18 Revenue;
IAS-21 The effect of changes in foreign exchange rates.
IAS-23 Borrowing Costs;
IAS-24 Related Parties Disclosure;
IAS-33 Earnings per Share;
IAS-34 Interim Financial Reporting;
IAS-36 Impairment of Assets;
IAS-37 Provisions, Contingent Liabilities and Contingent Assets;

IAS-38 Intangible Assets;
IFRS-1 First time adoption of International Financial Reporting Standards.
IFRS-7 Financial Instruments: Disclosures;
IFRS-9 Financial Instruments;
IFRS-13 Fair Value Measurement;
IFRS-15 Revenue from Contracts with Customers.

## 2.08 Property, Plant & Equipment:

### a. Recognition and Measurement:

In compliance with IAS-16 (Property, Plant & Equipment) items of Property, Plant & Equipment (PPE), excluding land are initially measured at cost less accumulated depreciation and accumulated impairment losses, if any. Land is measured at cost. The cost of an item of PPE comprises its purchase price, import duties and non-refundable taxes after deducting trade discount and rebates and any costs directly attributable to bringing the assets to the location and condition necessary for it to be capable of operating in the intended manner.

### b. Capitalization of Borrowing Cost:

Finance costs that are directly attributable to the construction of plants are included in the cost of those plants in compliance with IAS-23: Borrowing Cost, allowed alternative treatment.

### c. Subsequent Costs:

The cost of replacing part of an item of property, plant and equipment is recognized in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Company and its cost can be measured reliably. The cost of the day to day maintaining cost on PPE are recognized in the Statement of Comprehensive Income as incurred.

### d. Depreciation:

No depreciation is charged on land and land development.
Consistently, depreciation is provided on diminishing balance method based on written down value at which the asset is carried in the books of account. Depreciation continues to be provided until such time as the written down value is reduced to Taka one.
Each item of PPE is depreciated from the date in which the asset comes into use or capitalized. In case of disposals, no depreciation is charged in the month of disposal.
The depreciation/amortization rate(s) are as follows:

| Category of Fixed Assets | Rate % |
|---|---|
| Land & Land Development | - |
| Factory Buildings | 10 |
| Plant & Machinery | 10 |
| Generator | 10 |
| Office Decoration | 10 |
| Office Equipment | 15 |
| Furniture & Fixtures | 10 |
| Motor Vehicle | 10 |
| Books | - |
| Laboratory Test Equipment | 15 |

**e. Retirements and Disposals:**

An asset is derecognized on disposal or when no future economic benefits are expected from its use and subsequent disposal. Gains or losses arising from the retirement or disposal of an asset is determined as the difference between the net disposal proceeds and the carrying amount of the asset and is recognized as gain and loss from disposal of asset under other income in the Statement of Comprehensive Income.

**2.09 Intangible Assets:**

Intangible assets includes IT software which is used to maintain Company's accounts. It also includes Share Management Software and Website.

**a. Recognition and Measurement:**

Intangible assets are measured at cost less accumulated amortization and accumulated impairment loss, if any. It is recognized if it is probable that future economic benefits that are attributable to the asset will flow to the enterprise and cost of the assets can be measured reliably as required by IAS-38: Intangible assets. The cost of the Intangible assets comprises its purchase price and any costs directly attributable to the assets.

**b. Subsequent Costs:**

Subsequent expenditure is capitalized only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditures are recognized in the Statement of Comprehensive Income when incurred.

**c. Amortization:**

Amortization is recognized in the Statement of Comprehensive Income on diminishing balance method based on written down value at which the asset is carried in the books of account. Amortization continues to be provided until such time as the written down value is reduced to Taka one.

**2.10 Impairment of Assets:**

All assets have been reviewed according to IAS-36 and it was confirmed that no such assets have been impaired during the period and for this reason no provision has been made for impairment of assets.

**2.11 Inventories:**

Inventories are assets held for sale in the ordinary course of business, in the process of production for such sale or in the form of materials or supplies to be consumed in the production process. Inventories are stated at the lower of cost or net realizable value in compliance to the requirements of Para 21 and 25 of IAS-2. Costs including an appropriate portion of fixed and variable overhead expenses are assigned inventories by the method most appropriate to the particular class of inventory. Net realizable value represents the estimated selling price for the inventories less all estimated cost of completion and cost necessary to make the sale. Item wise valuation is as follows:

| **Category of Inventories** | **Basis of Valuation** |
|---|---|
| Raw & Packing Materials | At Weighted Average Cost |
| Work-in-Progress | At Standard Cost |
| Finished Goods | At Standard Cost |

Standard cost comprises value of materials, standard activity cost and overheads.

**2.12 Cash & Cash Equivalents:**

Cash & cash equivalents include cash in hand, cash at banks, term deposits which are available for use by the Company without any restrictions. There is an insignificant risk of change in value of the same.

**2.13 Accounts Receivable:**

Receivables are carried at original invoice amount. This is considered good for collection and therefore, no amount was written off as bad debt and no debt was considered doubtful to provide for.

**2.14 Creditors & Accrued Expenses:**

**2.14.1 Trade & Other Payables:**

Liabilities are recorded at the amount payable for settlement in respect of goods and services received by the Company.

**2.14.2 Provision:**

The preparation of financial statements are in conformity with Bangladesh Accounting Standards, IAS-37 Provisions, Contingent Liabilities and Contingent Assets requires management to make estimates and assumptions that affect the reported amounts of revenues and expenses, assets and liabilities, and the disclosure requirements for contingent assets and liabilities during and at the date of the financial statements.

**2.15 Employees' Benefit:**

Employees of the Company are entitled to get the following benefits from the Company:

**a. Festival Bonus:**

The Company gives 02 festival bonuses to its permanent employees in a year.

**b. Workers' Profit Participation Fund:**

This represents 5% of the net profit after charging such contribution but before tax contribution by the Company as per provisions of Bangladesh Labour Act (Amendments), 2013 and is payable to the workers as define in the said Law.

**2.16 Authorization date for issuing Financial Statements:**

The financial statements were authorized by the Board of Directors on 26 October 2026 for issue after completion of review.

**2.17 Income Tax:**

**2.17.1 Current Tax:**

Provision for taxation has been made as per rates prescribed in the Finance Act and the Income Tax Ordinance, 1984 on profit made by the company. As per IAS-12 Income Tax provision has been made during the year as the company earned taxable income.

**2.17.2 Deferred Tax:**

Deferred tax is recognized on differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit and are accounted for using the Statement of Financial Position as liability method. Deferred tax liabilities are generally recognized for all taxable temporary differences and deferred tax assets are generally recognized for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilized. CPL recognized deferred tax liabilities for all taxable temporary differences.

**2.18 Contingent Liabilities & Assets:**

Contingent liabilities and assets are current or possible obligations or assets, arising from past events and whose existence is due to the occurrence or non-occurrence of one or more uncertain future events which are not within the control of the Company. In accordance with IAS-37 Provision, Contingent Liabilities and Contingent Assets are disclosed in the notes to the financial statements.

**2.19 Revenue Recognition:**

Moment of recognition, amount to be recognized and disclosures requirements of revenue has been made as per IAS-18 "Revenue Recognition".

- The company recognized sales when products are invoiced and dispatched to the buyers;
- Interest income on bank deposit and short-term investments is recognized on receipts or due basis;
- Other income is recognized on receipt or due basis.

Revenue from sales is exclusive of VAT.

**2.20 Borrowing Costs:**

In compliance with the requirements of IAS-23 "Borrowing Costs", borrowing costs of operational period on long term loan and short-term loan facilities from commercial banks was charged off as revenue expenditure as they incurred.

**2.21 Foreign Currency Translation:**

Transactions in foreign currencies are translated to Bangladesh Taka at the foreign exchange rate ruling at the date of the transaction. Monetary assets and liabilities are converted at the rates prevailing at the Statement of Financial Position date. Non-monetary assets and liabilities denominated in foreign currencies, stated at historical cost are translated into Bangladesh Taka at the exchange rate ruling at the date of transaction.

**2.22 Statements of Cash Flows:**

Statement of Cash Flows is prepared principally in accordance with IAS-7: Cash Flow Statements and the cash flows from operating activities have been presented under direct method.

**2.23 Statement of Changes in Equity:**

The Statement of Changes in Equity reflects information about the increase or decrease in net assets or wealth.

**2.24 Earnings per Share:**

The Company calculates Earnings per Share (EPS) in accordance with IAS-33: "Earning per Share", which has been shown on the face of Statement of Profit or Loss and Other Comprehensive Income, and the computation of EPS is stated in the note.

**2.24.1 Basic Earnings:**

This represents earnings for the year attributable to the ordinary shareholders. As there was no preference dividend, minority interest or extra ordinary items, the net profit after tax for the period has been considered as fully attributable to ordinary shareholders.

**2.24.2 Basic Earnings per Share:**

This has been calculated by dividing the basic earnings by weighted average number of ordinary shares outstanding during the period.

**2.24.3 Diluted Earnings per Share:**

No diluted EPS is required to be calculated for the year, as there was no scope for dilution during the period under review.

**2.25 Comparative:**

Financial statements are presented as IAS-1 ''Presentation of Financial Statements" and previous year's figures have been restated due to changes in some accounting policies as per IAS-8 ''Accounting Policies, Changes in Accounting Estimates and Errors''.

**2.26 Reporting Period:**

The financial statements cover 01 (One) year from 01 July 2025 to 30 June 2026.

**2.27 Segment Reporting:**

No segmental reporting is applicable for the company as required by IAS-14: "Segment Reporting" as the company operates in a single industry segment and within a single geographical territory.

**2.28 Related Party Transactions:**

The objective of IAS-24 'Related Party Disclosures' is to ensure that an entity's financial statements contain the disclosures necessary to draw attention to the possibility that its financial position and profit or loss may have been affected by the existence of related parties and by transactions and outstanding balances with such parties.

Parties are considered to be related if one party has the ability to control the other party or to exercise significant influence or joint control over the other party in making financial and operating decisions.

A party is related to an entity if: [IAS-24] directly, or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with, the entity has an interest in the entity that gives it significant influence over the entity, has joint control over the entity, the party is a member of the key management personnel of the entity or its parent, the party is a close member of the family of any individual, the party is an entity that is controlled, jointly controlled or significantly influenced by or for which significant voting power in such entity resides with, directly or indirectly, any individual and the party is a post-employment benefit plan for the benefit of employees of the entity.

The Company transacts with related parties and recognize as per IAS-24 'Related Party Disclosures'. Related party transactions have been disclosed under Note -38.

**2.29 Interest paid and other Expenses:**

Interest paid and other expenses are recognized on accrual basis. But, the bank charged no interest during the period for rescheduling process.

**2.30 Repair upkeep and Maintenance Charges:**

There are usually absorbed as revenue charges as and when incurred.

**2.31 Preparation of Financial Position:**

The Board of Directors of the company is responsible for preparing & presentation of financial position of The Company.

**2.32 Bank Account:**

We have no bank Account except mentioned bank Account in the Financial position of the company.

**2.33 General:**

Wherever considered necessary, previous period's figures have been rearranged for the purpose of comparison;

Figures appearing in the financial statements have been rounded off to the nearest Taka.

| Notes | Particulars | Amount (TK) 30 June 2026 | Amount (TK) 30 June 2025 |
|---|---|---|---|
| **3.00** | **Property, Plant & Equipment:** | | |
| **A.** | **Cost:** | | |
| | Opening Balance | 1,690,440,278 | 1,690,440,278 |
| | Add: Addition during the year | - | - |
| | | **1,690,440,278** | **1,690,440,278** |
| **B.** | **Revaluation** | | |
| | Opening Balance | - | - |
| | Add: Addition during the year | - | - |
| | | - | - |
| **C.** | **Depreciation & Others** | | |
| | Opening Balance | 640,771,216 | 619,157,500 |
| | Add: Addition during the year | 19,430,824 | 21,613,716 |
| | | **660,202,040** | **640,771,216** |
| **D.** | **Impairment Loss** | | |
| | Opening Balance | - | - |
| | Add: Addition during the year | - | - |
| | | **-** | **-** |
| | **Written down value (A+B+C-D)** | **1,030,238,238** | **1,049,669,062** |
| | ***Details are given in Annexure-A with the report.** | | |
| **4.00** | **Intangible Assets:** | | |
| **A.** | **Cost:** | | |
| | Opening Balance | 327,500 | 327,500 |
| | Add: Addition during the year | - | - |
| | | **327,500** | **327,500** |
| **B.** | **Depreciation:** | | |
| | Opening Balance | 244,256 | 235,006 |
| | Add: Addition during the year | 8,324 | 9,250 |
| | | **252,580** | **244,256** |
| | **Written down value (A-B)** | **74,920** | **83,244** |
| | **Details are given in Annexure-B with the report.** | | |
| **5.00** | **Inventories:** | | |
| | Finished Goods | 2,802,536 | 2,283,105 |
| | Raw Materials | 3,027,698 | 1,977,880 |
| | Packing Materials | 5,004,929 | 3,382,894 |
| | Work-in-Process | 7,632,335 | 2,683,610 |
| | | **18,467,498** | **10,327,489** |
| | At the end of the year physical verification of Inventories was carried out by the Company management. The basis of valuation is stated in Note-2.11. | | |
| **6.00** | **Spare Parts & Supplies:** | | |
| | Spare Parts | 10,632,740 | 11,675,560 |
| | | **10,632,740** | **11,675,560** |
| **7.00** | **Advances, Deposits & Pre-payments:** | | |
| | Advance against Salary | - | - |
| | Advance Income Tax Note-7.01 | 286,625,356 | 286,623,405 |
| | Advance to Others | - | - |
| | **Deposits:** | | |
| | Security Deposit-Electricity | 382,000 | 382,000 |
| | Security Deposit-WASA (Deep Tube well) | 55,000 | 55,000 |
| | **Total** | **287,062,356** | **287,060,405** |

| Notes | Particulars | Amount (TK) 30 June 2026 | Amount (TK) 30 June 2025 |
|---|---|---|---|
| **7.01** | **Advance Income Tax** | | |
| | Opening Balance | 286,623,405 | 286,621,459 |
| | Add: Addition during the year | 1,951 | 1,946 |
| | | **286,625,356** | **286,623,405** |
| | Less: Adjustment | - | - |
| | | **286,625,356** | **286,623,405** |

Advance: These advances are un-secured but good and subsequently realized and/or adjusted.

Deposits: These balances represent security deposits made by the Company for electric connection, WASA, Office & Deport. rent etc.

In the opinion of the Directors, all current assets, investments, loans and advances are on realization in the ordinary course of business, a value at least equal to the amounts at which they are stated in the Statement of Financial Position.

There is no claim against the Company, which can be acknowledged as debt.

No amount was due by the Directors (including Managing Director) and managing agents of the Company and any of them severally or jointly with any other person.

| | | | |
|---|---|---|---|
| **8.00** | **Accounts Receivable:** | | |
| | Opening Balance | 68,904,410 | 73,253,141 |
| | Add: Sales made during the year | 36,620,272 | 33,058,631 |
| | | **105,524,682** | **106,311,772** |
| | Less: Received during the year | (33,822,511) | (32,756,042) |
| | Less: Bad Debts | (3,754,680) | (4,651,320) |
| | | **67,947,491** | **68,904,410** |
| | **Receivables against sales comprises followings:** | | |
| | Dhaka Sales Center | 67,947,491 | 68,904,410 |
| | **Total** | **67,947,491** | **68,904,410** |

The above amounts are unsecured but good and have been subsequently realized. No provision was made for bad debt during the year under review.

No amount was due by the Directors (including Managing Director) or any other official of the Company.

Aging of the above receivables is given below:

| Particulars | up to 1 month | 1-3 months | 3 to above | Total |
|---|---|---|---|---|
| Accounts Receivable | 3,154,580 | 5,874,720 | 58,918,191 | 67,947,491 |
| **Total** | **3,154,580** | **5,874,720** | **58,918,191** | **67,947,491** |

| | | | |
|---|---|---|---|
| **9.00** | **Cash & Bank Balances:** | | |
| | **Cash in Hand** | 7,678 | 2,082 |
| | **Cash at Bank:** | | |
| | Janata Bank Ltd., Local Office Br., (A/C No.-C.D 0100001407729) | 506,075 | 507,265 |
| | Janata Bank Ltd., Local Office Br., (A/C No.-STD 0100001434599) | 13,554 | 14,313 |
| | Janata Bank Ltd., Local Office Br., (A/C STD 0100001435081) IPO | 152,503 | 149,491 |
| | Janata Bank Ltd., Local Office Br., (A/C USD 0100198764242) (IPO) | 544,377 | 547,353 |
| | Janata Bank Ltd., Local Office Br., (A/C No.-BP 0100198746171) (IPO) | 9,357 | 10,013 |
| | Prime Bank Ltd. Motijheel Br. (A/C No. C.D 10411090062596) | - | - |
| | Islami Bank Bangladesh Limited; A/C-20502090100378300; Shyamoly Br. | 12,820 | 3,768 |
| | Social Islami Bank Ltd., Principal Br. (A/C No. 0021330449918) | - | - |
| | **Total** | **1,246,364** | **1,234,285** |

The bank balances have been confirmed and reconciled with respective bank statements.

Cash in hand has been verified by the Management at the close of the year and a cash custody certificate was furnished to the Auditors.

| Notes | Particulars | Amount (TK) 30 June 2026 | Amount (TK) 30 June 2025 |
|---|---|---|---|

**10.00 Share Capital:**

**Authorized Capital:**

| | | |
|---|---|---|
| 300,000,000 Ordinary Shares of Tk. 10.00 each | **3,000,000,000** | **3,000,000,000** |

**Issued, Subscribed and Paid-up:**

| | | |
|---|---|---|
| 119,800,844 Ordinary Shares of Tk. 10.00 each fully paid-up | **1,198,008,440** | **1,198,008,440** |

**Split of Face Value of Share:**

A special resolution is passed and duly certified from RJSC dated 24 December, 2009 to adopt a new Articles of Association. By the said special resolution, the Company's face value of share is reduced from Tk. 100 to Tk. 10.

**Shareholding Position is as follows:**

| Sl. No. | Name of shareholders | Percentage of Shareholdings | | Number of Shares | |
|---|---|---|---|---|---|
| | | 30 June 2026 | 30 June 2025 | 30 June 2026 | 30 June 2025 |
| 1 | Directors/Sponsors | 7.67 | 7.67 | 9,189,634 | 9,189,634 |
| 2 | Financial Institutions | 13.57 | 7.29 | 16,258,583 | 8,734,346 |
| 3 | General Public | 78.76 | 85.04 | 94,352,627 | 101,876,864 |
| **Total** | | **100.00** | **100.00** | **119,800,844** | **119,800,844** |

**Details of the Shareholding is given below:**

The distribution schedule showing the number of Shareholders and their shareholding in percentage has been disclosed below as the requirement of the “Listing Regulation” of Dhaka and Chittagong Stock Exchange Limited.

| Range of holdings in number of Shares | No. of Shareholders | | Holding % | |
|---|---|---|---|---|
| | 30 June 2026 | 30 June 2025 | 30 June 2026 | 30 June 2025 |
| Less than 500 shares | 3,335 | 1,519 | 0.83 | 0.38 |
| 501 to 5,000 shares | 5,800 | 9,336 | 10.40 | 16.74 |
| 5,001 to 10,000 shares | 1,442 | 2,233 | 6.33 | 9.81 |
| 10,001 to 20,000 shares | 910 | 543 | 22.19 | 13.24 |
| 20,001 to 30,000 shares | 363 | 167 | 20.28 | 9.33 |
| 30,001 to 40,000 shares | 189 | 146 | 7.30 | 10.61 |
| 40,001 to 50,000 shares | 165 | 131 | 7.80 | 6.75 |
| 50,001 to 100,000 shares | 268 | 86 | 8.11 | 9.14 |
| 100,001 to 1,000,000 shares | 145 | 56 | 9.09 | 16.33 |
| 1,000,001 to 10,000,000 shares | 2 | 2 | 7.67 | 7.67 |
| 10,000,001 to above shares | - | - | - | - |
| **Total** | **12,619** | **14,219** | **100.00** | **100.00** |

**Option on Un-Issued Shares:**

There is no option regarding the authorized capital not yet issued but can be used to increase the paid-up capital through the issuance of new shares against cash contribution and bonus.

**Market Price:**

The shares of the Company are listed with both the Dhaka and Chittagong Stock Exchange and quoted at Tk. 10.30 per share and Tk. 10.20 per share in the Dhaka and Chittagong Stock Exchange respectively on 30 June, 2026.

| Notes | Particulars | Amount (TK) 30 June 2026 | Amount (TK) 30 June 2025 |
|---|---|---|---|

**11.00 Revaluation Reserve:**

The Company revalued it's land and land development on 31 March, 2014 by Malek Siddik Wali & Co., Chartered Accountants for 1st time subsequently the company revalued all fixed assets 27 March 2024 by Rahman Mostafa Alam & Co. to reflect the up to date value of land and land development in the financial statements as at 30 June, 2023. Details of the revaluation of land and land development is given below:

| Particulars | Net Book Value Taka | Revalued Amount in Taka | Value increase due to Revaluation |
|---|---|---|---|
| Land & Land Development | 123,731,463 | 856,422,000 | 732,690,537 |
| **Total** | **123,731,463** | **856,422,000** | **732,690,537** |

**12.00 Retained Earnings:**

| | | |
|---|---|---|
| Opening Balance | (1,107,382,834) | (1,085,401,114) |
| Add: Profit during the year | (20,599,146) | (21,981,720) |
| Less: Cash dividend paid | - | - |
| Add: Prior year adjustment | - | - |
| Add: Interest weaver on Bank Loan for re-schedule | - | - |
| | **(1,127,981,980)** | **(1,107,382,834)** |

**13.00 Long Term Loan:**

| | | |
|---|---|---|
| Janata Bank Ltd., Local Office Br., Dhaka A/C No. 0100206078124 | 3,766,293 | 3,766,293 |
| Janata Bank Ltd., Local Office Br., Dhaka A/C No. 0100195236873 | 129,881,190 | 129,869,524 |
| Less: Current Portion | (17,905,932) | (17,905,932) |
| Janata Bank Ltd., Local Office Br., Dhaka A/C No. 0100206092194 | 134,838,934 | 134,838,934 |
| Less: Current Portion | (18,591,000) | (18,591,000) |
| | **231,989,485** | **231,977,819** |

The details of the loan is as under:
Nature: Long Term Project Loan (BMRE)
Sanction Limit: 159,688,000
Expiry Date: 30-09-2032
Interest Rate: 9.00%
Security: 34.30 katha land at 2A/1, South-West Darus Salam Road, Mirpur-1, Dhaka-1216.
The grace period of this re-scheduled loan is of 12 months and first installment will be started from 31 December, 2021. The term loan facility shall be repaid in equal 36 quarterly installments on repayment dates commencing from the immediate quarter-end upon the expiry of the grace period.

The details of the loan is as under:
Nature: CC Hypo (Working Capital)
Sanction Limit: 100,000,000
Expiry Date: 30-09-2031
Interest Rate: 9.00% (Variable)
Renewal Status: Renewed
Security: 34.30 katha land at 2A/1, South-West Darus Salam Road, Mirpur-1, Dhaka-1216 and personal guarantee of every Director.

**14.00 Deferred Tax Liabilities:**

| | | |
|---|---|---|
| Opening Balance | 29,390,908 | 30,305,419 |
| Add: (Reduction)/addition during the year | (2,962,771) | (914,511) |
| | **26,428,137** | **29,390,908** |

**15.00 Current Portion of Long Term Loan:**

| | | |
|---|---|---|
| Janata Bank Ltd., Local Office Br., Dhaka A/C No. 0100195236873 | 17,905,932 | 17,905,932 |
| Janata Bank Ltd., Local Office Br., Dhaka A/C No. 0100206092194 | 18,591,000 | 18,591,000 |
| | **36,496,932** | **36,496,932** |

The amount represents current maturity of Project Loan obtained from Janata Bank Ltd., Local Office Br., Dhaka which are payable within next 12 (twelve) months from the date of Statement of Financial Position.

| Notes | Particulars | Amount (TK) 30 June 2026 | Amount (TK) 30 June 2025 |
|---|---|---|---|
| **16.00** | **Sundry Creditors:** | | |
| | Bright International | 208,669 | 208,669 |
| | Brothers Trading | 503,068 | 603,068 |
| | Exotic Foils | 90,427 | 90,427 |
| | Nazmul & Brothers | 1,376,780 | 2,076,780 |
| | Prime Chemicals | 127,555 | 127,555 |
| | Refat Aluminum | 76,517 | 76,517 |
| | Roto Smart | 231,755 | 276,755 |
| | Spectrum Commi. | 13,849 | 13,849 |
| | Alok Trading | - | 5,639,247 |
| | ACI Ltd. | - | 100,000 |
| | Blusky Ltd. | 368,842 | 310,762 |
| | Bagdad Plastic | 219,960 | 339,960 |
| | Chem Fine | 1,264,500 | - |
| | Dhaka Foil Corp. | 1,566,441 | 2,456,770 |
| | Global Business Cor. | 5,086,000 | - |
| | Impex Corporation | 1,705,500 | - |
| | Mohammadia Trading | 814,047 | - |
| | Rasayan Ghar | 3,050,386 | |
| | Metro Foils Ltd. | 1,005,753 | - |
| | Sobuj Traders | 302,000 | - |
| | Relaiable Printers | 1,831,250 | - |
| | Dhaka Advertising | 170,750 | - |
| | M & S International | 1,827,512 | - |
| | Pharma Associates | 7,211,585 | 6,929,149 |
| | | **29,053,146** | **19,249,508** |

This represents amount payable to suppliers of raw materials, packing materials etc. All suppliers were paid on a regular basis.

| | | | |
|---|---|---|---|
| **17.00** | **Liabilities for Expenses:** | | |
| | Gas Bill-Factory | 139,208 | 30,642 |
| | Electricity-Factory | 851,520 | 788,026 |
| | Internet Bill | 23,600 | 33,350 |
| | WASA Bill-Factory | 77,645 | 43,746 |
| | Telephone-Factory | - | - |
| | Audit Fees | 287,500 | 230,000 |
| | | **1,379,473** | **1,125,764** |

Most of the outstanding liabilities have subsequently been paid;
No liabilities in the Statement of Financial Position are at a value less than the amount at which it is repayable at the date of the Statement of Financial Position.

| | | | |
|---|---|---|---|
| **17.01** | **Cash Dividend payable:** | **859,383** | **859,383** |
| | Cash Dividend payable represents unclaimed Cash Dividend payable Tk 859,383 for 583 shareholders. | | |

| | | | |
|---|---|---|---|
| **18.00** | **Others Payable:** | | |
| | Payable for IPO Proceeds | 5,962,694 | 5,962,694 |
| | **Total** | **5,962,694** | **5,962,694** |

Payable for IPO proceeds consists of subscription money of 1,198 applicants.

| | | | |
|---|---|---|---|
| **19.00** | **Provision for Tax Liabilities:** | | |
| | Opening Balance | 280,575,304 | 280,376,952 |
| | Add: Addition during the year | 183,101 | 198,352 |
| | | **280,758,405** | **280,575,304** |
| | Less: Adjustment | - | - |
| | | **280,758,405** | **280,575,304** |

| Notes | Particulars | | Amount (Tk) 2025-2026 | Amount (Tk) 2024-2025 |
|---|---|---|---|---|
| **20.00** | **Turnover:** | | | |
| | Local Sales (Net) | | 36,620,272 | 33,058,631 |
| | | | **36,620,272** | **33,058,631** |
| | Sales has been slightly increased than last year as per normal course of business. | | | |
| **21.00** | **Cost of Goods Sold:** | | - | |
| | Raw Material Consumed | (Note-21.01) | 20,771,942 | 14,128,021 |
| | Packing Material Consumed | (Note-21.02) | 2,909,328 | 1,413,239 |
| | Direct Expenses | (Note-21.03) | 4,136,280 | 3,627,094 |
| | Manufacturing Overhead | (Note-21.04) | 25,876,814 | 27,170,976 |
| | | | **53,694,364** | **46,339,330** |
| | Opening Work-in-Process | | 2,683,610 | 2,513,190 |
| | | | **56,377,974** | **48,852,520** |
| | Less: Closing Work-in-Process | | (7,632,335) | (2,683,610) |
| | | | **48,745,639** | **46,168,910** |
| | Opening Finished Goods | | 2,283,105 | 173,370 |
| | **Finished Goods available for Sale** | | **51,028,744** | **46,342,280** |
| | Less: Closing Finished Goods | | (2,802,536) | (2,283,105) |
| | | | **48,226,208** | **44,059,175** |
| **21.01** | **Raw Material Consumed:** | | | |
| | Opening Stock of Raw Materials | | 1,977,880 | 693,117 |
| | Add: Purchase of Raw Materials | | 21,821,760 | 15,412,784 |
| | | | **23,799,640** | **16,105,901** |
| | Less: Closing Stock of Raw Materials | | (3,027,698) | (1,977,880) |
| | | | **20,771,942** | **14,128,021** |
| **21.02** | **Packing Materials Consumed:** | | | |
| | Opening Stock of Packing Materials | | 3,382,894 | 1,613,741 |
| | Add: Purchase of Packing Materials | | 4,531,363 | 3,122,392 |
| | | | **7,914,257** | **4,736,133** |
| | Less: Closing Stock of Packing Materials | | (5,004,929) | (3,382,894) |
| | | | **2,909,328** | **1,353,239** |
| **21.03** | **Direct Expenses:** | | | |
| | Wages & Salary | | 3,711,560 | 3,512,314 |
| | Bonus | | 424,720 | 114,780 |
| | | | **4,136,280** | **3,627,094** |
| **21.04** | **Manufacturing Overhead:** | | | |
| | WASA Bill | | 267,483 | 274,132 |
| | Gas Bill | | 255,726 | 108,365 |
| | Electricity Bill | | 4,056,389 | 3,690,425 |
| | Telephone | | - | - |
| | Factory Maintenance | | 1,114,522 | 1,273,844 |
| | Machinery Maintenance | | 486,614 | 111,233 |
| | Spare Parts Consumption | | 1,042,820 | 1,124,576 |
| | Carriage Inward | | 184,354 | 43,481 |
| | Depreciation | | 18,468,906 | 20,544,920 |
| | | | **25,876,814** | **27,170,976** |

| Notes | Particulars | Amount (Tk) 2025-2026 | Amount (Tk) 2024-2025 |
|---|---|---|---|
| **22.00** | **Administrative Expenses:** | | |
| | Salary & Allowances | 4,176,860 | 3,674,780 |
| | Remmuneration | - | - |
| | Bonus | 254,620 | 233,540 |
| | Traveling & Conveyance | 131,320 | 84,354 |
| | Stationery | 194,970 | 176,311 |
| | Mobile Bill | 122,460 | 91,380 |
| | Internet Bill | 70,800 | 106,550 |
| | Renewal & Registration | 94,670 | 83,000 |
| | Postage & Telegram | 38,000 | 34,000 |
| | Stamp & Taxes | 108,000 | 109,000 |
| | Car Fuel | 176,000 | 165,000 |
| | Newspaper | 11,300 | 12,600 |
| | Office Maintenance | 76,000 | 8,400 |
| | Entertainment | 68,200 | 40,500 |
| | Repairs & Maintenance | 89,600 | 128,000 |
| | AGM Expenses | 612,800 | 354,000 |
| | Audit Fees | 287,500 | 230,000 |
| | Miscellaneous Expenses | 61,200 | 64,000 |
| | Legal Expenses | 26,400 | 12,000 |
| | Bad Debts | 3,754,680 | 4,651,320 |
| | Depreciation on Fixed Assets | 961,918 | 1,068,796 |
| | Amortization of Intangible Assets | 8,324 | 9,250 |
| | | **11,325,622** | **11,336,781** |
| **23.00** | **Selling & Distribution Expenses:** | | |
| | Salary & Allowances | - | - |
| | Sales Promotion & Business Development | - | - |
| | Bonus | - | - |
| | Carriage Outward | 411,840 | 360,580 |
| | Mobile Bill | - | - |
| | Postage | - | - |
| | TA/DA | - | - |
| | Utility | - | - |
| | Promotional & Literature Items Written Off | - | - |
| | | **411,840** | **360,580** |
| **24.00** | **Financial Expenses:** | | |
| | Janata Bank Ltd., Local Office Br., Dhaka A/C No. 0100195236873 | - | - |
| | Janata Bank Ltd., Local Office Br., Dhaka A/C No. 0100206092194 | - | - |
| | Janata Bank Ltd., Local Office Br., Dhaka A/C No. 0100206078124 | - | - |
| | Bank Charges & Commission | 16,968 | 6,459 |
| | | **16,968** | **6,459** |
| **25.00** | **Others Income:** | | |
| | Interest received from SND A/C with Janata Bank Ltd. | 559 | 594 |
| | Interest received from SND A/C with Janata Bank Ltd. (IPO) | 5,946 | 5,892 |
| | | **6,505** | **6,486** |

| Notes | Particulars | Amount (Tk) 2025-2026 | Amount (Tk) 2024-2025 |
|---|---|---|---|

**26.00 Contribution to Workers' Profit Participation Fund:**

This represents 5% of the net profit after charging such contribution but before tax contribution by the Company as per provisions of Bangladesh Labour Act (Amendments), 2013.

**27.00 Income Tax Expenses:**

| | | |
|---|---|---|
| Current Tax (Note-27.01) | 183,101 | 198,352 |
| Deferred Tax (Note-27.02) | (2,962,771) | (914,511) |
| | **(2,779,670)** | **(716,159)** |

**27.01 Current Tax:**

**Calculation of Current Tax:**

| | | |
|---|---|---|
| Corporate Tax on 22.50% and/or 25% | - | - |
| Turnover Tax is 0.50% | 183,101 | 198,352 |
| **Current Tax is Higher on the above, so current tax is** | **183,101** | **198,352** |

**27.02 Deferred Tax:**

| | | |
|---|---|---|
| Closing Deferred Tax Liabilities | 26,428,137 | 29,390,908 |
| Opening Deferred Tax Liabilities | (29,390,908) | (30,305,419) |
| **Current year Deferred Tax** | **(2,962,771)** | **(914,511)** |

**28.00 Earnings per Share (EPS):**

The Computation of EPS is given below:

| | | |
|---|---|---|
| Earning attributable to the Shareholders (net profit after tax) | (20,610,812) | (21,981,719) |
| Number of Shares outstanding during the year | 119,800,844 | 119,800,844 |
| **Earnings per Share (EPS)** | **(0.17)** | **(0.18)** |

EPS has been decreased due to increase in loss made as per normal course of business.

**29.00 Net Asset Value (NAV) per Share:**

The Computation of NAV is given below:

| | | |
|---|---|---|
| Net Assets | 802,716,997 | 823,316,144 |
| Number of Shares outstanding during the year | 1,198,008,844 | 119,800,844 |
| **Net Asset Value per Share (NAV)** | **6.70** | **6.87** |

NAV has been increased due to increase in net assets during the year.

**30.00 Net Operating Cash Flows per Share (NOCFPS):**

The Computation of NOCPS is given below:

| | | |
|---|---|---|
| Net Cash Generated from Operating Activities | 17,381 | (522,357) |
| Weighted average number of Shares | 119,800,844 | 119,800,844 |
| **Net Operating Cash Flows per Share (NOCFPS)** | **0.00** | **(0.00)** |

The NOCFPS has been increased due to collection of receivables.

| Notes | Particulars | Amount (Tk) 2025-2026 | Amount (Tk) 2024-2025 |
|---|---|---|---|
| 30.01 | **Reconciliation of Net Profit with Cash Flows from Operating Activities:** | | |
| | This is made up as follows: | | |
| | **Net Profit/(Loss) after Tax** | **(20,574,191)** | **(21,981,719)** |
| | (As per Statement of Profit or Loss and Other Comprehensive Income) | | |
| | **Add/(Less) Adjustments:** | **17,978,523** | **28,667,046** |
| | Depreciation on Fixed Assets | 19,430,824 | 21,622,966 |
| | Change in Inventories | (8,140,009) | (5,334,071) |
| | Change in Spare Parts & Supplies | (1,042,820) | (1,124,576) |
| | Change in Advances, Deposits & Pre-payments | (1,951) | (1,946) |
| | Change in Accounts Receivable | 956,919 | 4,348,731 |
| | Change in Deferred Tax Liabilities | (2,962,772) | (914,511) |
| | Change in Sundry Creditors | 9,803,638 | 10,432,256 |
| | Change in Liabilities for Expenses | (253,709) | (566,614) |
| | Change in Dividend payable | - | - |
| | Change in Others Payable | - | - |
| | Change Provision for Tax Liabilities | 183,101 | 198,352 |
| | Impairment Loss | - | - |
| | Financial Expenses | 5,302 | 6,459 |
| | **Cash Flows from Operating Activities** | **29,047** | **(522,357)** |
| | (As per Statement of Cash Flows) | | |
| 31.00 | **Related Notes for Statement of Cash Flows:** | | |
| 31.01 | **Collection from Customers & Others:** | | |
| | Turnover from P/L | 36,620,272 | 33,058,631 |
| | Change in Accounts Receivable | (2,797,761) | (302,589) |
| | Non Operating Income | 6,505 | 6,486 |
| | | **33,829,016** | **32,762,528** |
| 31.02 | **Cash Paid to Others** | | |
| | Income Tax Paid | 1,951 | (1,946) |
| | | **(1,951)** | **(1,946)** |

**32.00 Commission, Brokerage or Discount:**

No brokerage and discount against sales was paid during the year.

**33.00 Payment made in Foreign Currency:**

No expenses including Royalty, Technical Experts & Professional Advisory Fees and Interest etc. were incurred or paid in foreign currencies during the financial year.

**34.00 Finance Lease Commitment:**

As at 30 June, 2026, there was no lease commitment under finance lease.

**35.00 Claim not Acknowledged as debt:**

There was no claim against the company acknowledged as debt as on 30 June, 2026.

**36.00 Related Party Transactions:**

The Company has no related party transactions as per IAS-24 Related Party Disclosures for the year ended 30 JUNE 2026.

| Name of the Directors | Designation | Basic Salary | Others | Total |
|---|---|---|---|---|
| Mr. Munsur Ahamed | Managing Director | - | - | - |
| **Total** | | **-** | **-** | **-** |

Compensation package of key management personnel**:**

| Particulars | Amount |
|---|---|
| Short-term employee benefit | - |
| Post employee benefit | - |
| Other long-term benefit | - |
| Termination benefit | - |
| Share-based payment | - |
| **Total** | **-** |

Details break-down of related party transaction:

**a) The amount of Transactions:**

| Name of party | Relation/Basis of Control | Purpose | Amount |
|---|---|---|---|
| Munsur Ahamed | Managing Director of the Company | Executive Compensation | - |

**b) The amount of outstanding Balance:**

| Name of party | Outstanding Balance | Terms & Condition | Detail of Guarantee |
|---|---|---|---|
| Mr. Munsur Ahamed | Nil | Nil | Nil |

**c) Provision for doubtful debts related to the amount of outstanding Balance:**

| Name of party | Outstanding Balance | Provision for Doubtful Debts |
|---|---|---|
| Mr. Munsur Ahamed | Nil | Nil |

d) The expense recognized as bad or doubtful debts:

| Name of party | Outstanding Balance | Bad or Doubtful Debts |
|---|---|---|
| Mr. Munsur Ahamed | Nil | Nil |

(a) no compensation was made to the Managing Director of the company except as stated above
(b) no amount was spent by the company for compensating any member of the Board of Directors except as stated in above.

**37.00 Attendance Status of Board Meeting of Directors**

During the year ended 30 June, 2026 there were eight Board Meetings were held. The attendance status of all the meetings is as follows:

| Name of the Directors | Designation | Meeting held | Attendance |
|---|---|---|---|
| Mrs. Morsheda Ahmed | Chairman | 08 | 08 |
| Mr. Munsur Ahamed | Managing Director | 08 | 08 |
| Mohammad Abdul Motaleb | Independent Director | 08 | 06 |
| Md. Nazrul Islam Bhuiyan | Independent Director | 08 | 07 |
| Md. Shafiqul Islam | Independent Director | 08 | 08 |

**38.00 Payment/Perquisites to Directors:**

During the year no other compensation was allowed by the company to the Directors except executive compensation received by Chairman as Director (Admin.) and Managing Director.

No amount of money was expended by the company for compensating any member of the board special services rendered other than the above.

No board meeting attendance fees was paid to the Directors of the Company.

**39.00 Audit Fees:**

Auditors remuneration comprises annual audit fees only.

**40.00 Un-availed Credit Facilities:**

There are no credit facilities available to the Company under any contract (other than credit available in ordinary course of business) at the Statement of Financial Position date .

**41.00** No board meeting attendance fees has been given to the Board of Directors.

**42.00 Contingent Liabilities:**

**a.** The company has a contingent liability aggregating Taka 7,382,136 claimed by VAT Authority as VAT & penalty on differential amount of sales against production during the year May 2005 to June 2008. The Company has made deposition several times to concern VAT Authority with proper grounds protesting the claim. As such the Company has filed petition to the High Court which is Subjudice.

Commissioner, Customs Excise & VAT, Dhaka-West Dhaka issued a show cause notice demanding VAT on dispute matters like value addition and legal point. Therefore, the company has submitted a writ petition before the Supreme Court of Bangladesh in High Court Division. Honorable High Court heard on the matter about show cause notice and issued a rule and stay order on the above mentioned show cause notice. Government submitted a writ petition before the Supreme Court for stay order allow on the rule. The Supreme Court also directed the Honorable High Court Division for hearing on the matter as early as possible. Now it is under High Court Division for hearing. There is no updated status till 11 October 2026.

**b.** The company has another contingent liability aggregating Taka 204,878,950 claimed by VAT Authority as VAT & penalty on differential amount of sales against production during the year 2010-2011 to 2014-2015. The Company has made deposition several times to concern VAT Authority with proper grounds protesting the claim. As such the Company has filled petition to the High Court which is Subjudice. There is no updated status till 11 October 2026.

**c.** The company has another contingent liability aggregating Taka17,864,965 claimed by VAT Authority as VAT & Penalty on differential amount of sales against production during the year October 2014 to January 2017. The Company has made deposition several times to concern VAT Authority with proper grounds protesting the claim. As such the Company has filed petition to the High Court which is Subjudice.There is no updated status till 11 October 2026.

**43.00 Internal Control:**

The following steps have been taken for implementation of an effective internal control procedure of the company:

a. A strong internal control and compliance division has been formed with a view to establish a well designated system of internal control;

b. Regular review of internal audit reports with a view to implement the suggestion of internal auditors in respect of internal control technique;
c. To establish an effective management system that includes planning, organizing and supervising culture in the factory as well as at head office.

**44.00 Segment Reporting:**

As there is single business and geographic segment within the company operates as such no segment reporting is felt necessary.

**45.00 General:**

figure.

The comparative information has been disclosed of 2025-2026 for all numerical information in the financial statements and also the narrative and descriptive information as found relevant for understanding of the current years financial statements.

To facilitate comparison, certain relevance balances pertaining to the previous year have been rearranged or reclassified whenever considered necessary to conform to current year presentation.

**46.00 Events after reporting period:**

The is no significant events after reporting period.

**47.00 Financial Risk Measurement:**

The management of Company has overall responsibility for the establishment and oversight of the Company's risk management framework. Risk management policies, procedures and systems are reviewed regularly to reflect changes in market conditions and the Company's activities. The Company has exposure to the following risks for its use of financial instruments.

-Credit risk;
-Liquidity risk;
-Market risk;
- Currency risk.

**Credit risk:**

Credit risk is the risk of a financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations and arises principally from the Company's receivables. Management has a credit policy in place and exposure to credit risk is monitored on an ongoing basis. Risk exposures from other financial assets, i.e. cash at bank and other external receivables are nominal.

**Liquidity risk:**

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company's approach to managing liquidity (cash and cash equivalents) is to ensure as far as possible, that it will always have sufficient cash and cash equivalent to meet expected operational expenses including financial obligations through preparation of the cash flow forecast with due consideration of time line of payment of the financial obligation and accordingly arrange for sufficient liquidity/fund to make the expected payment within due date.

**Market risk:**

Market is the risk that any change in market prices such as foreign exchange rates and interest will affect the Company's income or the value of its holdings financial instruments. The objective of the market risk management is to manage and control market risk exposures within acceptable parameters.

**Currency risk:**

The Company is exposed to currency risk on certain revenues and purchases such as revenue from foreign customers and import of raw materials, machineries and equipment. Majority of the Company's foreign currency transactions are denominated in USD and relate to procurement of raw materials, machineries and equipment from abroad.

**48.00 Disclosure as per requirement of Schedule XI, Part II of the Companies Act, 1994:**

**A.** Disclosure as per requirement of Schedule XI, Part II, Note 5 of Para 3:
Employee position of the company as at 30 June, 2026

| Salary (Monthly) | Officer & Staff | | Worker | Total Employees |
|---|---|---|---|---|
| | Factory | Head Office | | |
| Below Tk. 8,000/- | 15 | - | 36 | 51 |
| Above Tk. 8,000/- | 24 | 1 | - | 25 |
| **for the year ended 30-06-2026** | **40** | **1** | **38** | **79** |
| **for the year ended 30-06-2025** | **39** | **1** | **36** | **76** |

**B. Disclosure as per requirement of Schedule XI, Part II, Para 4:**

| Name of Directors | Designation | Basic Salary | Others | Total payment on 30-06-2026 | Total payment on 30-06-2025 |
|---|---|---|---|---|---|
| Mrs. Morsheda Ahmed | Chairman | - | - | - | - |
| Mr. Munsur Ahamed | Managing Director | - | - | - | - |
| Mrs. Arjuman Naziz | Independent Director | - | - | - | - |
| Mr. Md. Abdur Rahman (Rakib) | Independent Director | - | - | - | - |
| Mr. Abdul Motalab | Independent Director | - | - | - | |
| **Total** | | **-** | **-** | **-** | **-** |

Period of payment to Directors is from 01 July, 2025 to 30 June, 2026.
The above Directors of the company did not take any benefit from the Company and the follows:

a. Expenses reimbursed to the managing agent-Nil
b. Commission or other remuneration payable separately to a managing agent or his associate-Nil
c. Commission received or receivable by the managing agent or his associate as selling or buying agent of other concerns in respect of contracts entered into such concerns with the company-Nil
d. The money value of the contracts for the sale or purchase of goods and materials or supply of services, enter into by the company with the managing agent or his associate during the financial year-Nil
e. Any other perquisites or benefits in cash or in kind stating-Nil
f. Other allowances and commission including guarantee commission-Nil

Pensions, etc.-

1) Pensions-Nil
2) Gratuities-Nil
3) Payment from Provident Fund-Nil
4) Compensation for loss of office-Nil
5) Consideration in connection with retirement from office-Nil

**C. Disclosure as per requirement of Schedule XI, Part II, Para 7:**

Details of production capacity utilization:

| Item | Unit | Production Capacity | Actual Production | Capacity Utilization |
|---|---|---|---|---|
| Tablet & Capsule | Million Pcs | 160 | 42.92 | 26.83% |
| Liquid & Ointment | Million Pcs | - | - | 0.00% |

**D. Disclosure as per requirement of Schedule XI, Part II, Para 8:**

Raw materials, spare parts, packing materials and capital machinery:

| Items | Total Purchase (BDT) | Consumption (BDT) | % of consumption of |
|---|---|---|---|
| Raw Materials | 21,821,760 | 20,771,942 | 95.19% |
| Packing Materials | 4,531,363 | 2,909,328 | 64.20% |
| Spare Parts | - | 1,042,820 | 0.00% |
| **Total** | **26,353,123** | **24,724,090** | |

i) The company has not incurred any expenditure in foreign currencies for the period from 01 July, 2025 to 30 June, 2026 on account of royalty, know-how, professional fees, consultancy fees and interest;

ii) The company has not earned any foreign exchanges for royalty, know-how, professional fees, consultancy fees and interest;

iii) No export has been made during the period from 01 July, 2025 to 30 June, 2026.

**E. Disclosure as per requirement of Schedule XI, Part II, Para 3:**

| Requirements under Condition No. | Compliance status of disclosure of Schedule XI, Part II, Para 3 |
|---|---|
| 3(i)(a) The turnover. | Complied |
| 3 (i)(b) Commission paid to the selling agent. | Not Applicable |
| 3(i)(c ) Brokerage and discount on sales, other than the usual trade discount | Not Applicable |
| 3(i)(d)(i) The value of the raw materials consumed, giving item wise as possible. | Complied |
| 3(i)(d)(ii) The opening and closing stocks of goods produced. | Complied |
| 3(i)(e) In the case of trading companies, the purchase made and the opening and closing stocks. | Complied |
| 3(i)(f) In the case of companies rendering or supplying services, the gross income derived from services rendered or supplied. | Not Applicable |
| 3(i)(g) Opening and closing stocks, purchases and sales and consumption of raw materials with value and quantity break-up for the company, which falls under one or more categories i.e. manufacturing and/or trading. | Complied |
| 3(i)(h) In the case of other companies, the gross income derived under different heads | Not Applicable |
| 3(i)(i) Work-in-progress, which have been completed at the commencement and at the end of the accounting period. | Complied |
| 3(i)(j) Provision for depreciation, renewals or diminution in value of fixed assets. | Complied |
| 3(i)(k) Interest on the debenture paid or payable to the Managing Director, Managing Agent and Manager. | Not Applicable |
| 3(i)(l) Charge of income tax and other taxation on profits. | Complied |
| 3(i)(m) Revised for repayment of share capital and repayment of loans. | Complied |
| 3(i)(n)(i) Amount set aside or proposed to be set aside, to reserve, but not including provisions made to meet any specific liability, contingency or commitment, know to exist at the date as at which the balance sheet is made up. | Not Applicable |
| 3(i)(n)(ii) Amount withdrawn from above mentioned reserve | |
| 3(i)(o)(i) Amount set aside to provisions made for meeting specific liabilities, contingencies of commitments. | Not Applicable |
| 3(i)(o)(ii) Amount withdrawn from above mentioned provisions, as no longer required. | Not Applicable |
| 3(i)(p) Expenditure incurred on each of the following items, separately for each item: (i) Consumption of stores and spare parts (ii) Power and Fuel (iii) Rent (iv) Repairs of Buildings (v) Repairs of Machinery (vi) (1) Salaries, wages and bonous (2) Contribution to provident and other funds (3) Worksmen and staff welfare expenses to the extent not adjusted from any previous provision or reserve. | Complied |

**F. Disclosure of Advances, Deposits and Pre-payments of Schedule XI of the Companies Act, 1994:**

The details break-up of Advances, Deposits and Pre-payments as per requirement of Schedule XI of the Companies Act, 1994 as stated below:

| Particulars | 30 June 2026 | 30 June 2025 |
|---|---|---|
| Advances, Deposits and Pre-payments exceeding 6 months | 287,062,356 | 287,060,405 |
| Advances, Deposits and Pre-payments not exceeding 6 months | Nil | Nil |
| Other Advances, Deposits & Pre-payments less provision | Nil | Nil |
| Advances, Deposits and Pre-payments considered good and secured | Nil | Nil |
| Advances, Deposits and Pre-payments considered goods without security | Nil | Nil |
| Advances, Deposits and Pre-payments considered doubtful or bad | Nil | Nil |
| Advances, Deposits and Pre-payments due by Directors | Nil | Nil |
| Advances, Deposits and Pre-payments due by other officers (against salary) | - | - |
| Advances, Deposits and Pre-payments due from companies under same management | - | - |
| Maximum Advances, Deposits & Pre-payments due by Directors | Nil | Nil |
| Maximum Advances, Deposits & Pre-payments due by Officers at any time | Nil | Nil |

These financial statements should be read in conjunction with the annexed notes and were approved by the Board of Directors on 11 October 2026 and were signed on its behalf by :

# CENTRAL PHARMACEUTICALS LIMITED

**Schedule of Property, Plant & Equipment**

**FOR THE YEAR ENDED 30 JUNE 2026**

**Annexure-A**

| Particulars | Cost | | | | Depreciation | | | | Written down value as at 30 June 2026 |
|---|---|---|---|---|---|---|---|---|---|
| | Balance as at 01 July 2025 | Addition during the year | Revaluation Reserve | Balance as at 30 June 2026 | Rate % | Balance as at 01 July 2025 | Charged during the year | Balance as at 30 June 2026 | |
| Land & Land Development | 856,422,000 | - | - | 856,422,000 | - | - | - | - | 856,422,000 |
| Factory Building | 188,011,368 | - | - | 188,011,368 | 10% | 138,241,817 | 4,976,955 | 143,218,772 | 44,792,596 |
| Plant & Machinery | 573,454,000 | - | - | 573,454,000 | 10% | 446,089,640 | 12,736,436 | 458,826,076 | 114,627,924 |
| Electric Equipment | 8,641,920 | - | - | 8,641,920 | 10% | 4,745,493 | 389,643 | 5,135,136 | 3,506,784 |
| Office Decoration | 17,682,707 | - | - | 17,682,707 | 10% | 13,029,631 | 465,308 | 13,494,939 | 4,187,768 |
| Office Equipment | 9,381,223 | - | - | 9,381,223 | 10% | 8,121,571 | 125,965 | 8,247,536 | 1,133,687 |
| Furniture & Fixture | 13,086,326 | - | - | 13,086,326 | 10% | 9,548,287 | 353,804 | 9,902,091 | 3,184,235 |
| Motor Vehicle | 4,537,506 | - | - | 4,537,506 | 10% | 4,369,096 | 16,841 | 4,385,937 | 151,569 |
| Books | 158,399 | - | - | 158,399 | 0% | - | - | - | 158,399 |
| Laboratory Test Equipment | 19,064,829 | - | - | 19,064,829 | 15% | 16,625,681 | 365,872 | 16,991,553 | 2,073,276 |
| **As at 30-06-2026** | **1,690,440,278** | **-** | **-** | **1,690,440,278** | | **640,771,216** | **19,430,824** | **660,202,040** | **1,030,238,238** |
| **As at 30-06-2025** | **1,690,440,278** | **-** | **-** | **1,690,440,278** | | **619,157,500** | **21,613,716** | **640,771,216** | **1,049,669,062** |

| Allocation of Depreciation: | Amount (Tk) 2025-2026 | Amount (Tk) 2024-2025 |
|---|---|---|
| Impairment Loss | - | - |
| Manufacturing Overhead | 18,468,906 | 20,544,920 |
| Administrative | 961,918 | 1,068,796 |
| **Total** | **19,430,824** | **21,613,716** |

# CENTRAL PHARMACEUTICALS LIMITED

**Schedule of Intangible Assets**

**FOR THE YEAR ENDED 30 JUNE 2026**

| Particulars | Cost | | | | Depreciation | | | | Written down value as at 30 June 2026 |
|---|---|---|---|---|---|---|---|---|---|
| | Balance as at 01 July 2025 | Addition during the year | Revaluation Reserve | Balance as at 30 June 2026 | Rate % | Balance as at 01 July 2025 | Charged during the year | Balance as at 30 June 2026 | |
| IT Software-Accounting Software | 75,000 | - | - | 75,000 | 10% | 55,937 | 1,906 | 57,843 | 17,157 |
| Share Management Software | 200,000 | - | - | 200,000 | 10% | 149,163 | 5,084 | 154,247 | 45,753 |
| Website Development | 52,500 | - | - | 52,500 | 10% | 39,156 | 1,334 | 40,490 | 12,010 |
| **As at 30-06-2026** | **327,500** | **-** | **-** | **327,500** | | **244,256** | **8,324** | **252,580** | **74,920** |
| **As at 30-06-2025** | **327,500** | **-** | **-** | **327,500** | | **235,006** | **9,250** | **244,256** | **83,244** |

# CENTRAL PHARMACEUTICALS LIMITED

**Deferred Tax Shedule**

**FOR THE YEAR ENDED 30 JUNE 2026**

**Annexure-A**

| Particulars | Cost | | | | Depreciation | | | | Written down value as at 30 June 2026 |
|---|---|---|---|---|---|---|---|---|---|
| | Balance as at 01 July 2025 | Addition during the year | Revaluation Reserve | Balance as at 30 June 2026 | Rate % | Balance as at 01 July 2025 | Charged during the year | Balance as at 30 June 2026 | |
| Land & Land Development | 856,422,000 | - | - | 856,422,000 | - | - | - | - | 856,422,000 |
| Factory Building | 188,011,368 | - | - | 188,011,368 | 10% | 172,677,410 | 1,533,396 | 174,210,806 | 13,800,562 |
| Plant & Machinery | 573,454,000 | - | - | 573,454,000 | 10% | 531,880,536 | 4,157,346 | 536,037,882 | 37,416,118 |
| Electric Equipment | 8,641,920 | - | - | 8,641,920 | 10% | 8,015,410 | 62,651 | 8,078,061 | 563,859 |
| Office Decoration | 17,682,707 | - | - | 17,682,707 | 10% | 16,240,529 | 144,218 | 16,384,747 | 1,297,960 |
| Office Equipment | 9,381,223 | - | - | 9,381,223 | 10% | 8,616,102 | 76,512 | 8,692,614 | 688,609 |
| Furniture & Fixture | 13,086,326 | - | - | 13,086,326 | 10% | 12,019,022 | 106,730 | 12,125,752 | 960,574 |
| Motor Vehicle | 4,537,506 | - | - | 4,537,506 | 10% | 4,208,552 | 32,895 | 4,241,447 | 296,059 |
| Books | 158,399 | - | - | 158,399 | 25% | 152,584 | 1,454 | 154,038 | 4,361 |
| Laboratory Test Equipment | 19,064,829 | - | - | 19,064,829 | 10% | 17,509,927 | 155,490 | 17,665,417 | 1,399,412 |
| **As at 30-06-2026** | **1,690,440,278** | **-** | **-** | **1,690,440,278** | | **771,320,072** | **6,270,692** | **777,590,764** | **912,849,514** |
| **As at 30-06-2025** | **1,472,597,830** | **-** | **-** | **1,690,440,278** | | **764,352,314** | **6,967,758** | **764,352,314** | **919,120,206** |

**CENTRAL PHARMACEUTICALS LIMITED**

**Deferred Tax Shedule**

**FOR THE YEAR ENDED 30 JUNE 2026**

| Particulars | Cost | | | | Depreciation | | | | Written down value as at 30 June 2026 |
|---|---|---|---|---|---|---|---|---|---|
| | Balance as at 01 July 2025 | Addition during the year | Revaluation Reserve | Balance as at 30 June 2026 | Rate % | Balance as at 01 July 2025 | Charged during the year | Balance as at 30 June 2026 | |
| IT Software-Accounting Software | 75,000 | - | - | 75,000 | 10% | 73,661 | 134 | 73,795 | 1,205 |
| Share Management Software | 200,000 | - | - | 200,000 | 10% | 196,431 | 357 | 196,788 | 3,212 |
| Website Development | 52,500 | - | - | 52,500 | 10% | 51,563 | 94 | 51,657 | 843 |
| **As at 30-06-2026** | **327,500** | **-** | **-** | **327,500** | | **321,655** | **585** | **322,240** | **5,260** |
| **As at 30-06-2025** | **327,500** | **-** | **-** | **327,500** | | **321,005** | **650** | **321,655** | **5,845** |

**Calculation of Deferred Tax Liabilities as on 30 June, 2026:**

| Particulars | Carrying Amount | Tax Base | Tax Rate<br>Temporary Difference | 22.50%<br>DTL (+) / DTA (-) |
|---|---|---|---|---|
| **NON-CURRENT AND CURRENT ASSETS** | | | | |
| Property, Plant & Equipment | 1,030,238,238 | 912,849,514 | 117,388,724 | 26,412,463 |
| Intangible Assets | 74,920 | 5,260 | 69,660 | 15,674 |
| **Deferred Tax Liability** | | | | **26,428,136** |

**So, Deferred Tax Expense/(Income) for the period from 01 July, 2025 to 30 June, 2026 is as follows:**

| | |
|---|---|
| Deferred Tax Liability as on 30 June, 2026 | 26,428,137 |
| Deferred Tax Liability as on 30 June, 2025 | 29,390,908 |
| **Deferred Tax (Income) for the year ended 30 June, 2026** | **(2,962,771)** |